MEDCL.PA Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 geg. 2024 @ 18:35):

Stats
Dzisiejszy wolumen	139 014
Średni wolumen	74 842.00
Kapitalizacja rynkowa	415.28M
EPS	€0 ( 2023-12-18 )
Następna data zysków	( €0 ) 2024-06-24
Last Dividend	€0 ( N/A )
Next Dividend	€0 ( N/A )
P/E	-14.16
ATR14	€0.0260 (0.18%)

Wolumen Korelacja

Długi: -0.07 (neutral)

Krótki: 0.01 (neutral)

Signal:(45.857) Neutral

Medincell SA Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Medincell SA Korelacja - Waluta/Towar

-0.49
( neutral )

-0.52
( weak negative )

0.00
( neutral )

0.03
( neutral )

0.08
( neutral )

Medincell SA Finanse

Annual	2022
Przychody:	€9.89M
Zysk brutto:	€13.66M (138.08 %)
EPS:	€-1.270

FY	2022
Przychody:	€9.89M
Zysk brutto:	€13.66M (138.08 %)
EPS:	€-1.270

FY	2022
Przychody:	€4.09M
Zysk brutto:	€4.09M (100.00 %)
EPS:	€-1.070

FY	2021
Przychody:	€8.19M
Zysk brutto:	€6.74M (82.27 %)
EPS:	€-0.946

Financial Reports:

No articles found.

Medincell SA

MedinCell S.A. develops various therapeutic solutions. It develops solutions based on BEPO, a technology for long-acting injectable products based on proprietary copolymers and a biocompatible solvent, which solubilizes or suspends the active pharmaceutical ingredients. The company's products in development include mdc-IRM, a subcutaneous injection in Phase III trials for use in the treatment of schizophrenia; mdc-CWM, an intra-articular injection to treat pain and inflammation; and mdc-TJK, a subcutaneous injection in preclinical trials for use in the treatment of schizophrenia. Its product candidates in formulation research comprise subcutaneous injections, such as mdc-WWM for contraception; mdc-ANG for CNS related treatments; mdc-ELK for depression; and mdc-GRT for use in organ transplant, as well as perineural injections, including mdc-CMV for anesthesia and pain, and mdc-NVA for pain. The company is based in Jacou, France.